^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    simtuzumab (GS 6624)

    i
    Other names: GS 6624, AB 0024, AB-0024, AB0024, GS-6624
    Associations

    News

    Trials
    Company:
    Gilead
    Drug class:
    VEGFR inhibitor, CXCL12 inhibitor, TGF-β1 inhibitor, Connective tissue growth factor inhibitor, LOXL2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over4years
    [VIRTUAL] Serum bile acid species are associated with liver fibrosis and clinical disease progression in patients with primary sclerosing cholangitis (EASL-ILC-I 2020)
    Levels of 15 BAs and the BA intermediate, 7α-hydroxy-4-cholesten-3-one (C4), were quantified by LC-MS/MS (Agilent 1290/Sciex, Metabolon) in fasting serum samples from patients with compensated large-duct PSC at baseline (BL) in a 96-week, phase 2 trial of simtuzumab (NCT01672879)... In patients with compensated PSC, total serum BAs, as well as conjugated primary BAs, are markers of liver fibrosis and predict clinical disease progression. These data support ongoing evaluation of therapies that reduce BA levels (e.g. FXR agonists) for the treatment of PSC.
    Clinical
    |
    FGF19 (Fibroblast growth factor 19) • FGF (Fibroblast Growth Factor)
    |
    simtuzumab (GS 6624)